Lantheus (NASDAQ:LNTH) Issues FY 2024 Earnings Guidance

Lantheus (NASDAQ:LNTH) issued an update on its FY 2024 earnings guidance on Wednesday morning. The company provided EPS guidance of 6.650-6.700 for the period, compared to the consensus EPS estimate of 6.660. The company issued revenue guidance of $1.5 billion-$1.5 billion, compared to the consensus revenue estimate of $1.5 billion. Lantheus also updated its FY24 guidance to $6.65-6.70 EPS.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on LNTH shares. JMP Securities cut their price target on Lantheus from $125.00 to $112.00 and set a “market outperform” rating for the company in a research note on Thursday. Leerink Partners upped their target price on Lantheus from $106.00 to $127.00 and gave the stock an “outperform” rating in a research note on Thursday, July 11th. Truist Financial restated a “buy” rating and set a $120.00 price objective (down from $135.00) on shares of Lantheus in a research report on Friday. Redburn Atlantic initiated coverage on shares of Lantheus in a research note on Tuesday, September 3rd. They set a “buy” rating and a $175.00 target price for the company. Finally, B. Riley boosted their price target on Lantheus from $105.00 to $146.00 and gave the stock a “buy” rating in a research report on Thursday, July 25th. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $122.50.

Lantheus Trading Down 2.2 %

Shares of LNTH traded down $1.98 during mid-day trading on Friday, hitting $86.34. The company had a trading volume of 1,115,587 shares, compared to its average volume of 990,638. Lantheus has a 1-year low of $50.20 and a 1-year high of $126.89. The company has a quick ratio of 4.41, a current ratio of 4.68 and a debt-to-equity ratio of 0.55. The business’s 50-day simple moving average is $107.71 and its 200-day simple moving average is $95.52. The stock has a market cap of $5.99 billion, a PE ratio of 14.66 and a beta of 0.51.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings results on Wednesday, November 6th. The medical equipment provider reported $1.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.40 by $0.08. The firm had revenue of $378.73 million during the quarter, compared to the consensus estimate of $373.58 million. Lantheus had a return on equity of 48.36% and a net margin of 29.80%. Sell-side analysts forecast that Lantheus will post 5.99 earnings per share for the current year.

Insider Transactions at Lantheus

In related news, Director Gerard Ber sold 15,500 shares of the stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $96.48, for a total value of $1,495,440.00. Following the completion of the transaction, the director now owns 21,221 shares in the company, valued at $2,047,402.08. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 2.10% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.